Dr. Martens plc
DOCS.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.17 | -0.28 | -0.40 | 0.03 |
| FCF Yield | 36.22% | 15.67% | 1.82% | 6.67% |
| EV / EBITDA | 6.68 | 6.40 | 7.31 | 9.63 |
| Quality | ||||
| ROIC | 3.68% | 11.01% | 16.96% | 26.64% |
| Gross Margin | 64.97% | 65.58% | 61.79% | 63.72% |
| Cash Conversion Ratio | 43.62 | 2.43 | 0.60 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.66% | -1.16% | 8.97% | 10.55% |
| Free Cash Flow Growth | 27.31% | 438.61% | -83.75% | 60.20% |
| Safety | ||||
| Net Debt / EBITDA | 2.25 | 1.86 | 1.25 | 0.63 |
| Interest Coverage | 1.92 | 4.08 | 10.33 | 16.53 |
| Efficiency | ||||
| Inventory Turnover | 1.47 | 1.19 | 1.48 | 2.68 |
| Cash Conversion Cycle | 237.86 | 293.72 | 216.38 | 112.60 |